4-(3-Methylbut-1-ynyl)pyridazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(3-Methylbut-1-ynyl)pyridazine
• 英文别名: 4-(3-methylbut-1-ynyl)pyridazine
• 化学式: C₉H₁₀N₂
• 分子量: 146.19
• InChiKey: GLWFUDXWUMNRKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• US20140274884A1
  申请人：——

  公开号：US20140274884A1

  公开（公告）日：2014-09-18
• Factor D Inhibitors Useful for Treating Inflammatory Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170226142A1

  公开（公告）日：2017-08-10

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
• US9617310B2
  申请人：——

  公开号：US9617310B2

  公开（公告）日：2017-04-11
• [EN] AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS AMIDE POUR LE TRAITEMENT DE TROUBLES MÉDIÉS PAR LE COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2015130795A1

  公开（公告）日：2015-09-03

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
• [EN] AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS AMINÉS POUR TRAITER LES TROUBLES À MÉDIATION PAR LE COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2015130806A1

  公开（公告）日：2015-09-03

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.